Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scion Accuses Abbott Of Misappropriating Clo-Sur Wound Dressing Secrets

This article was originally published in The Gray Sheet

Executive Summary

Scion Cardio-Vascular, Inc. is accusing Abbott Laboratories of lifting elements of its Clo-Sur P.A.D. marketing campaign, among other infractions, in a six-count complaint filed Nov. 22 in Miami federal court

You may also be interested in...



Scion v. Abbott

Scion Cardio-Vascular drops suit accusing Abbott of misappropriating Clo-Sur P.A.D. wound dressing trade secrets. The firm says it will conserve resources for marketing efforts (1"The Gray Sheet" Dec. 9, 2002, p. 18)...

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel